Technology area: Biotechnology & Pharmaceuticals
58 pending office actions • 41 art units • 55 examiners • 0 of 58 (0%) have an AI response strategy ready • 56 patents granted in the last 365 days
United States Department of Veterans Affairs has 18 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 18 distinct examiners and 16 distinct art units, indicating a widely distributed examiner docket with some art-unit repetition.
NG, JONATHAN K is the busiest examiner, with 1 pending matter. Because no examiner carries a repeated assignment in the reported data, prosecution management should emphasize standardized review, clear technical disclosures, and matter-specific response preparation.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 7 (12%) |
| §103 only | 14 (24%) |
| §102 only | 1 (2%) |
| §112 only | 3 (5%) |
| Double-patenting only | 3 (5%) |
| Double-patenting + other | 2 (3%) |
| Multi-statute (no §101) | 27 (47%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 3 | 33.3% | +61.1% |
| PIPIC, ALMA | 2 | 54.8% | +54.3% |
| NG, JONATHAN K | 1 | 35.6% | +14.2% |
| SCHAETZLE, KENNEDY | 1 | 83.7% | +8.2% |
| LI, LARRY | 1 | 66.7% | +66.7% |
| RAUBENSTRAW, TYLER ALLEN | 1 | 71.2% | +30.6% |
| GINES, GEORGE SAMUEL | 1 | 71.4% | +41.3% |
| HOLTZCLAW, MICHAEL T. | 1 | 78.0% | +15.5% |
| KOO, BENJAMIN K | 1 | 57.3% | +49.7% |
| MILLER, WILLIAM L | 1 | 79.0% | +14.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18483225 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | LEE, CHIHYI NMN | 18d overdue |
| 18276871 | METHODS OF TREATING HYPOGONADOTROPIC HYPOGONADISM AND COGNITION IMPAIRMENT FOLLOWING A TRAUMATIC BRAIN INJURY | JOHNSON, TIRONE DEREK | 6d |
| 18464152 | COMBINATION THERAPY FOR INFLAMMATORY DISEASES | KARUNASENA, ENUSHA | 14d |
| 18749726 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | LEE, CHIHYI NMN | 34d |
| 18015169 | BIOFLUID-BASED PROTEIN AND MIRNA BIOMARKERS FOR NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | MCCOLLUM, ANDREA K | 60d |
| 19225745 | FOUR-COMPARTMENT DIFFUSION MODEL OF INSULIN IN HUMANS | NG, JONATHAN K | — |
| 19027952 | Stereotactic Multifocal Recording And Stimulation Device And Methods Of Use | SCHAETZLE, KENNEDY | — |
| 18907722 | Disinfection System For Wheelchairs | LI, LARRY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18483225 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | LEE, CHIHYI NMN | 18d overdue |
| 18749726 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | LEE, CHIHYI NMN | 34d |
| 19225745 | FOUR-COMPARTMENT DIFFUSION MODEL OF INSULIN IN HUMANS | NG, JONATHAN K | — |
| 18907722 | Disinfection System For Wheelchairs | LI, LARRY | — |
| 18886302 | Electronic Nasal Cannula Flame Detector And Oxygen Shutoff Device | RAUBENSTRAW, TYLER ALLEN | — |
| 18885039 | Assistive Positioning Device For A Limb Of A Patient | GINES, GEORGE SAMUEL | — |
| 18826930 | Cuff For Providing Vagus Nerve Stimulation | HOLTZCLAW, MICHAEL T. | — |
| 18737593 | Medication Delivery Device | KOO, BENJAMIN K | — |
| Art Unit | Apps |
|---|---|
| 1628 | 4 |
| 1658 | 3 |
| 1617 | 3 |
| 3791 | 3 |
| 1624 | 3 |
| 3796 | 2 |
| 3783 | 2 |
| 1675 | 2 |
| 1626 | 2 |
| 1638 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19225745 | FOUR-COMPARTMENT DIFFUSION MODEL OF INSULIN IN HUMANS | NG, JONATHAN K | 3619 | §101DP | Non-Final OA | — | Pending | Jun 02, 2025 |
| 19027952 | Stereotactic Multifocal Recording And Stimulation Device And Methods Of Use | SCHAETZLE, KENNEDY | 3796 | §101DP | Final Rejection | — | Pending | Jan 17, 2025 |
| 18907722 | Disinfection System For Wheelchairs | LI, LARRY | 2881 | §102§103§112 | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18886302 | Electronic Nasal Cannula Flame Detector And Oxygen Shutoff Device | RAUBENSTRAW, TYLER ALLEN | 3785 | §103 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18885039 | Assistive Positioning Device For A Limb Of A Patient | GINES, GEORGE SAMUEL | 2884 | §103 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18826930 | Cuff For Providing Vagus Nerve Stimulation | HOLTZCLAW, MICHAEL T. | 3796 | §102§103 | Final Rejection | — | Pending | Sep 06, 2024 |
| 18749726 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | 34d | Pending | Jun 21, 2024 |
| 18737593 | Medication Delivery Device | KOO, BENJAMIN K | 3783 | §102§103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18639153 | Headstone Socket Preserver | MILLER, WILLIAM L | 3677 | §112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18406868 | CLINICAL SYSTEM INTEGRATION | TOMASZEWSKI, MICHAEL | 3681 | §103 | Final Rejection | 28d | Pending | Jan 08, 2024 |
| 18502774 | Needle Assembly With Integrated Curvature Mechanism | NICHOLS, CHARLES W | 3783 | §102§103 | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18276871 | METHODS OF TREATING HYPOGONADOTROPIC HYPOGONADISM AND COGNITION IMPAIRMENT FOLLOWING A TRAUMATIC BRAIN INJURY | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Final Rejection | 6d | Pending | Aug 10, 2023 |
| 18038588 | COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR | KOMATSU, LI N | 1658 | DP | Final Rejection | 14d | Pending | May 24, 2023 |
| 18074364 | EVALUATION OF BRAIN TISSUE AND MATERIAL BASED ON A FRACTION-PRODUCT AND OPTICAL SPECTROSCOPY | DO, AN H | 1687 | §101 | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17910637 | A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma | HALVORSON, MARK | 1646 | §103Other | Final Rejection | 2d overdue | Pending | Sep 09, 2022 |
| 17711782 | Ear Stent And Methods Of Using Same | BLASS, PARIS MARIE | 3774 | §103 | Final Rejection | 29d | Pending | Apr 01, 2022 |
| 17639265 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | PIPIC, ALMA | 1617 | §103 | Non-Final OA | — | Pending | Feb 28, 2022 |
| 17288849 | COMPOSITIONS AND METHODS FOR SELECTING BIALLELIC GENE EDITING | DUNN, MCKENZIE A | 1678 | §103 | Final Rejection | 88d overdue | Pending | Apr 26, 2021 |
| 19109022 | METHODS AND SYSTEMS FOR PREDICTING HEALTH RISKS | PARK, EVELYN GRACE | 3791 | §101§102 | Non-Final OA | — | Pending | Mar 05, 2025 |
| 18991111 | Methods for Organizing the Disinfection of one or More Items Contaminated with Biological Agents | PHAM, TOAN NGOC | 2685 | §103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18979814 | Methods And Kits For Assessing Central Nervous System Integrity | CERIONI, DANIEL LEE | 3791 | DP | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18812628 | METHODS AND KITS FOR DIAGNOSING, ASSESSING OR QUANTITATING DRUG USE, DRUG ABUSE AND NARCOSIS, INTERNUCLEAR OPHTHALMOPLEGIA, ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), CHRONIC TRAUMATICENCEPH ALOPATHY,SCHIZOPHRENIA SPECTRUM DISORDERS AND ALCOHOL CONSUMPTION | GEBREMICHAEL, BRUK A | 3715 | DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18834436 | A MECHANO-RESPONSIVE NANOFIBROUS PATCH FOR THE DELIVERY OF BIOLOGICS IN LOAD-BEARING TISSUES | BAZARGANI, ARYA AHMADI | 1613 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18775053 | Diagnosis and Treatment of Metabolic Syndrome with Magnesium Compositions | PIPIC, ALMA | 1617 | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18735087 | MICRORNA-541-3P AS A THERAPEUTIC AGENT AS WELL AS ZNF101 AND CASZ1 AS THERAPEUTIC TARGETS TO LOWER PLASMA LDL-C, INCREASE PLASMA HDL-C, AND REDUCE ATHEROSCLEROSIS | QIAN, CELINE X | 1637 | §102§103§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18671007 | Non-Toxin Antigens For Clostridioides Difficile Vaccine | GRASER, JENNIFER E | 1645 | §101§102§112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18710037 | METHOD OF TREATING CANCER ASSOCIATED WITH RAS MUTATION | BRAUN, MADELINE E | 1624 | §102§103§112Other | Non-Final OA | — | Pending | May 14, 2024 |
| 18644608 | MEK1/2 INHIBITOR-LOADED MICROPARTICLE FORMULATION | PALLAY, MICHAEL B | 1617 | §103 | Final Rejection | 40d | Pending | Apr 24, 2024 |
| 18700605 | BACTERIOPHAGE PREPARATIONS AND METHODS OF USE | ALAM, DANYAL HASSAN | 1672 | §102§103§112Other | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18684563 | TREATMENT COMPOSITIONS AND METHODS | HEASLEY, MEGHAN CHRISTINE | 1626 | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18417617 | COMPOSITIONS AND METHODS FOR SPATIAL AND TEMPORAL CONTROL OF NEUROTROPHIC GROWTH FACTOR EXPRESSION | AMICK, THOMAS RUSSE | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18573604 | Compounds For Molecular Imaging of Collagen Turnover and Methods Using Same | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18390242 | COMPOSITIONS AND METHOD FOR TREATING GUT PERMEABILITY CAUSED BY HYDROGEN SULFIDE PRODUCING BACTERIA | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18533784 | COMPOSITIONS AND METHODS FOR TREATING RIGHT VENTRICLE DYSFUNCTION | ZARA, JANE J | 4100 | §102§103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18566564 | METHODS AND COMPOSITIONS FOR LOCALIZATION OF GROWTH FACTORS | BERHANE, SELAM | 1675 | §103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18563088 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | DAVIS, RUTH A | 1699 | §103§112DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18506916 | aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER | JAVANMARD, SAHAR | 1622 | §102§103§112Other | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18483225 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | LEE, CHIHYI NMN | 1628 | §103§112Other | Final Rejection | 18d overdue | Pending | Oct 09, 2023 |
| 18372662 | MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18464152 | COMBINATION THERAPY FOR INFLAMMATORY DISEASES | KARUNASENA, ENUSHA | 1653 | §102§103§112 | Final Rejection | 14d | Pending | Sep 08, 2023 |
| 18547837 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18274293 | COMPOSITIONS AND METHODS FOR INHIBITING YAP | COUGHLIN, MATTHEW P | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18271631 | GENETIC THERAPY FOR GLAUCOMA AND OPTIC NEUROPATHIES | YU, DELPHINUS DOU YI | 1636 | §112 | Final Rejection | — | Pending | Jul 10, 2023 |
| 18336712 | THE MODE OF ACTION OF N-MeDCPA ON TRPC CHANNELS | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18267038 | DIAGNOSTICS AND THERAPEUTICS FOR EBV IN MS AND OTHER AUTOIMMUNE DISEASES | KAPUSHOC, STEPHEN THOMAS | 1683 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | HOWELL, THEODORE R | 1628 | §103 | Final Rejection | 78d overdue | Pending | May 09, 2023 |
| 18301093 | Human Adipose-Derived Stem Cell Exosomes And Their Packaging For Use At Room Temperature | CONNORS, ALEXANDRA F | 1634 | §103 | Final Rejection | 29d | Pending | Apr 14, 2023 |
| 18043163 | HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF | RAO, PADMAJA S | 1627 | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18015169 | BIOFLUID-BASED PROTEIN AND MIRNA BIOMARKERS FOR NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | MCCOLLUM, ANDREA K | 1674 | §101§102§112 | Non-Final OA | 60d | Pending | Jan 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnited States Department of Veterans Affairs has 58 pending office actions as of October 2026, spread across 41 art units and 55 examiners.
Chihyi Nmn Lee has the most, with 3 of United States Department of Veterans Affairs's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
